CBL-514 is under clinical development by Caliway Biopharmaceutics and currently in Phase II for Adiposis Dolorosa (Dercum’s Disease or Anders Disease). According to GlobalData, Phase II drugs for ...

The CBL-514 injection lipolysis therapy is intended for subcutaneous fat reduction. Credit: CHAjAMP / Shutterstock. Taiwanese biopharmaceutical company Caliway Biopharmaceuticals has announced that a ...

Leon H. Charney Division of Cardiology (M.C., M.D.), NYU School of Medicine, New York. Inherited Arrhythmias Clinic and Heart Rhythm Center, Leon H. Charney Division ...

From the Inherited Cardiovascular Disease Group, University College London, The Heart Hospital, London, United Kingdom (S.S.C., W.J.M.); and Department of ...

New therapeutic options in the management of superficial fungal diseases.